中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

经内镜逆行胰胆管造影术后胰腺炎的药物预防

王艾 赵礼金

引用本文:
Citation:

经内镜逆行胰胆管造影术后胰腺炎的药物预防

DOI: 10.3969/j.issn.1001-5256.2017.01.043
详细信息
  • 中图分类号: R657.51

Research advances in pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography

  • 摘要:

    经内镜逆行胰胆管造影(ERCP)已逐渐成为诊治胆胰管疾病的重要手段之一。ERCP术后胰腺炎(PEP)是其最常见的严重并发症,近几年发生率已升至40%。如何预防PEP一直是临床研究的热点。对药物预防PEP的研究进展进行了综述,认为目前仍需大样本量的临床对照试验对预防药物是否有效进行证实,且最佳用药时间、给药途径、剂量等方面也需进一步探究;此外,不同国家的人口特点、各年龄阶段人群均需列入临床研究的考虑范围之内。

     

  • [1] Chinese Society of Digestive Endoscopy,Chinese Medical Association Pancreatic Disease Committee of Chinese Medical Doctor Association.Expert consensus on pharmacological prevention of pancreatitis after endoscopic retrograde cholangiopancreatography(2015,Shanghai)[J].J Clin Hepatol,2016,32(5):830-834.(in Chinese)中华医学会消化内镜学分会,中国医师协会胰腺病专业委员会.内镜下逆行胰胆管造影术后胰腺炎药物预防专家共识意见(2015年,上海)[J].临床肝胆病杂志,2016,32(5):830-834.
    [2]TESTONI PA,MARIANI A,GIUSSANI A,et al.Risk factors for post-ERCP pancreatitis in high-and low-volume centers and among expert and non-expert operators:a prospective multicenter study[J].Am J Gastroenterol,2010,105(8):1753-1761.
    [3]GOTTLIEB K,SHERMAN S.ERCP and biliary endoscopic sphincterotomy-induced pancreatitis[J].Gastrointest Endosc Clin N Am,1998,8(1):87-114.
    [4]FREEMAN ML.Adverse outcomes of endoscopic retrograde cholangiopancreatography:avoidance and management[J].Gastrointest Endosc Clin N Am,2003,13(4):775-798.
    [5]COTTON PB,LEHMAN G,VENNES J,et al.Endoscopic sphincterotomy complications and their management:an attempt at consensus[J].Gastrointest Endosc,1991,37(3):383-393.
    [6]FREEMAN ML,NELSON DB,SHERMAN S,et al.Complications of endoscopic biliary sphincterotomy[J].N Engl J Med,1996,335(13):909-918.
    [7]BANKS PA,BOLLEN TL,DERVENIS C,et al.Classification of acute pancreatitis—2012:revision of the Atlanta classification and definitions by international consensus[J].Gut,2013,62(1):102-111.
    [8]ARTIFON EL,CHU A,FREEMAN M,et al.A comparison of the consensus and clinical definitions of pancreatitis with a proposal to redefine post-endoscopic retrograde cholangiopancreatography pancreatitis[J].Pancreas,2010,39(4):530-535.
    [9]DELLINGER EP,FORSMARK CE,LAYER P,et al.Determinant-based classification of acute pancreatitis severity:an international multidisciplinary consultation[J].Ann Surg,2012,256(6):875-880.
    [10]GEORGE S,KULKARNI AA,STEVENS G,et al.Role of osmolality of contrast media in the development of post-ERCP pancreatitis:a metanalysis[J].Dig Dis Sci,2004,49(3):503-508.
    [11]YIERPAN AS,GAO F.Risk factors for hyperamylasemia after endoscopic retrograde cholangiopancreatography[J].J Clin Hepatol,2016,32(1):119-122.(in Chinese)依尔潘·艾山,高峰.经内镜逆行胰胆管造影术后高淀粉酶血症的危险因素分析[J].临床肝胆病杂志,2016,32(1):119-122.
    [12]DING X,ZHANG F,WANG Y.Risk factors for post-ERCP pancreatitis:a systematic review and meta-analysis[J].Surgeon,2015,13(4):218-229.
    [13]ANDRIULLI A,LOPERFIDO S,NAPOLITANO G,et al.Incidence rates of post-ERCP complications:a systematic survey of prospective studies[J].Am J Gastroenterol,2007,102(8):1781-1788.
    [14]ANDRADE-DAVILA VF,CHAVEZ-TOSTADO M,DAVALOSCOBIAN C,et al.Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography:results of a controlled clinical trial[J].BMC Gastroenterol,2015,15:85.
    [15]PATIL S,PANDEY V,PANDAV N,et al.Role of rectal diclofenac suppository for prevention and its impact on severity of postendoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients[J].Gastroenterology Res,2016,9(2-3):47-52.
    [16]LEVENICK JM,GORDON SR,FADDEN LL,et al.Rectal indomethacin does not prevent post-ercp pancreatitis in consecutive patients[J].Gastroenterology,2016,150(4):911-917.
    [17]PARK SW,CHUNG MJ,OH TG,et al.Intramuscular diclofenac for the prevention of post-ERCP pancreatitis:a randomized trial[J].Endoscopy,2015,47(1):33-39.
    [18]DUMONCEAU JM,ANDRIULLI A,DEVIERE J,et al.European Society of Gastrointestinal Endoscopy(ESGE)guideline:prophylaxis of post-ERCP pancreatitis[J].Endoscopy,2010,42(6):503-515.
    [19]HANNA MS,PORTAL AJ,DHANDA AD,et al.UK wide survey on the prevention of post-ERCP pancreatitis[J].Frontline Gastroenterol,2014,5(2):103-110.
    [20]DUMONCEAU JM,ANDRIULLI A,ELMUNZER BJ,et al.Prophylaxis of post-ERCP pancreatitis:European Society of Gastrointestinal Endoscopy(ESGE)guideline-updated June 2014[J].Endoscopy,2014,46(9):799-815.
    [21]AKBAR A,ABU DAYYEH BK,BARON TH,et al.Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography:a network meta-analysis[J].Clin Gastroenterol Hepatol,2013,11(7):778-783.
    [22]de QUADROS ONOFRIO F,LIMA JC,WATTE G,et al.Prophylaxis of pancreatitis with intravenous ketoprofen in a consecutive population of ERCP patients:a randomized double-blind placebo-controlled trial[J].Surg Endosc,2016.[Epub ahead of print]
    [23]ANDRIULLI A,LEANDRO G,NIRO G,et al.Pharmacologic treatment can prevent pancreatic injury after ERCP:a meta-analysis[J].Gastrointest Endos,2000,51(1):1-7.
    [24]ANDRIULLI A,CARUSO N,QUITADAMO M,et al.Antisecretory vs.antiproteasic drugs in the prevention of post-ERCP pancreatitis:the evidence-based medicine derived from a meta-analysis study[J].JOP,2003,4(1):41-48.
    [25]ANDRIULLI A,LEANDRO G,FEDERICI T,et al.Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP:an updated meta-analysis[J].Gastrointest Endos,2007,65(4):624-632.
    [26]DEENADAYALU VP,BLAUT U,WATKINS JL,et al.Does obesity confer an increased risk and/or more severe course of post-ERCP pancreatitis:a retrospective,multicenter study[J].J Clin Gastroenterol,2008,42(10):1103-1109.
    [27]ZHANG Y,CHEN QB,GAO ZY,et al.Meta-analysis:octreotide prevents post-ERCP pancreatitis,but only at sufficient doses[J].Aliment Pharmacol Ther,2009,29(11):1155-1164.
    [28]QIN X,LEI WS,XING ZX,et al.Prophylactic effect of somatostatin in preventing Post-ERCP pancreatitis:an updated meta-analysis[J].Saudi J Gastroenterol,2015,21(6):372-378.
    [29]YUHARA H,OGAWA M,KAWAGUCHI Y,et al.Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis:protease inhibitors and NSAIDs in a meta-analysis[J].J Gastroenterol,2014,49(3):388-399.
    [30]LUMAN W,PRYDE A,HEADING RC,et al.Topical glyceryl trinitrate relaxes the sphincter of Oddi[J].Gut,1997,40(4):541-543.
    [31]STARITZ M,PORALLA T,EWE K,et al.Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure[J].Gut,1985,26(2):194-197.
    [32]BRANDSTATTER G,SCHINZEL S,WURZER H.Influence of spasmolytic analgesics on motility of sphincter of Oddi[J].Dig Dis Sci,1996,41(9):1814-1818.
    [33]DING J,JIN X,PAN Y,et al.Glyceryl trinitrate for prevention of post-ERCP pancreatitis and improve the rate of cannulation:a meta-analysis of prospective,randomized,controlled trials[J].PLo S One,2013,8(10):e75645.
    [34]KUBILIUN NM,ADAMS MA,AKSHINTALA VS,et al.Evaluation of pharmacologic prevention of pancreatitis after endoscopic retrograde cholangiopancreatography:a systematic review[J].Clin Gastroenterol Hepatol,2015,13(7):1231-1239.
    [35]SHAO LM,CHEN QY,CHEN MY,et al.Nitroglycerin in the prevention of post-ERCP pancreatitis:a meta-analysis[J].Dig Dis Sci,2010,55(1):1-7.
    [36]LEE TY,CHOI JS,OH HC,et al.Oral udenafil and aceclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients:a randomized multicenter study[J].Korean J Intern Med,2015,30(5):602-609.
    [37]CHOI JH,KIM HJ,LEE BU,et al.Vigorous periprocedural hydration with lactated ringer's solution reduces the risk of pancreatitis after retrograde cholangiopancreatography in hospitalized patients[J].Clin Gastroenterol Hepatol,2017,15(1):86-92.
    [38]ELMUNZER BJ.Aggressive intravenous fluid resuscitation for preventing post-endoscopic retrograde cholangiopancreatography pancreatitis:finally on the right track[J].Clin Gastroenterol Hepatol,2014,12(2):308-310.
    [39]GRUNWALD D,WADHWA V,SAWHNEY MS.Hemodynamic variation and intravenous fluids administered during ERCP and the association with post-ERCP pancreatitis[J].Pancreas,2016,45(2):293-297.
    [40]GOOSHE M,ABDOLGHAFFARI AH,NIKFAR S,et al.Antioxidant therapy in acute,chronic and post-endoscopic retrograde cholangiopancreatography pancreatitis:an updated systematic review and meta-analysis[J].World J Gastroenterol,2015,21(30):9189-9208.
    [41]FUENTES-OROZCO C,DAVALOS-COBIAN C,GARCIACORREA J,et al.Antioxidant drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis:what does evidence suggest?[J].World J Gastroenterol,2015,21(21):6745-6753.
  • 加载中
计量
  • 文章访问数:  1907
  • HTML全文浏览量:  42
  • PDF下载量:  399
  • 被引次数: 0
出版历程
  • 出版日期:  2017-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回